Copyright by Alice Zhao 2016

Total Page:16

File Type:pdf, Size:1020Kb

Copyright by Alice Zhao 2016 Copyright by Alice Zhao 2016 The Dissertation Committee for Alice Zhao certifies that this is the approved version of the following dissertation: Cytoplasmic foci at the crossroads of artifactual science and biological function Committee: Edward M. Marcotte, Supervisor Andrew D. Ellington Yan (Jessie) Zhang Dean R. Appling Vishwanath R. Iyer Cytoplasmic foci at the crossroads of artifactual science and biological function by Alice Zhao, B.S.Bio DISSERTATION Presented to the Faculty of the Graduate School of The University of Texas at Austin in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY THE UNIVERSITY OF TEXAS AT AUSTIN MAY 2016 Dedication To my mother. The simplest lessons turn out to be the most important. And to those who (have) dedicate(d) their lives to open-access and transparency. Acknowledgements With great appreciation, I acknowledge the following individuals for their contributions to various aspects of my development as a scientist and a person. This body of research could not have been accomplished without their help, to each I owe my very deep gratitude. I would like to thank members of the Marcotte lab, former and current, for all have helped or influenced me in some way. Through the comradery of tackling science, I have learned valuable lessons from each and every one of us. In particular, I thank Traver Hart for his excellent mentorship which recruited me into graduate studies. I thank the expert adviser Zhihua Li, for his wealth of knowledge on experimental techniques. I thank Mark Tsechansky for his persistent encouragement and earnest fascination with science. I thank Jagannath Swaminathan, Dan Boutz, Fan Tu, and Anna Battenhouse for their skillful help and expertise at critical points of each project. I also thank Jeremy O’Connell, Kevin Drew, and Chris Yellman, for their kind and patient guidance. I thank the core proteomics facility staff and the sequencing facility staff, who have all consistently and reliably aided me with my questions on sample processing and analysis. I thank my committee members, Dr. Andy Ellington, Dr. Yan Jessie Zhang, Dr. Dean Appling, Dr. Vishy Iyer, and Dr. Edward Marcotte for their courageous support, motivation, and valuable inputs. I especially thank Edward Marcotte for being an exceptional role model for me and for generously providing me with an amazing environment to tinker and explore. I further extend my thanks to the students, post-docs, and faculty from various other labs and institutes who have given me their valuable advice, materials, and time. I am also thankful for the support and diligence from past and present administrative staff of the building and of the department, and for the cheery custodial team with whom I’ve spent many late evenings. Finally, I thank my friends and family for all of their love and support over the years, without which this work would not have been possible. v Cytoplasmic foci at the crossroads of artifactual science and biological function Publication No. ______ Alice Zhao, Ph.D. The University of Texas at Austin, 2016 Supervisor: Edward M. Marcotte Deciphering protein interaction and compartmentalization is crucial to understanding the molecular mechanisms that drive biological processes. Using various high throughput approaches, we have managed to score subcellular dynamic protein re-organization into supramolecular structures and map physical association networks to discover protein complexes on a proteome-wide level. However, the case by case studies of some of these novel structures and interactions reveal difficulties in interpreting their biological basis. This study offers insights into limits inherent in the molecular techniques used to investigate subcellular structures and protein interactions, describing a set of cautionary tales and critical analysis for deciphering cases of confounding data from orthogonal approaches. This study also offers a new experimental technique for high-throughput imaging assays with mammalian cell lines. vi Table of Contents Acknowledgements ........................................................................................ v List of Tables ............................................................................................. xiv List of Figures ............................................................................................. xv Introduction .................................................................................................. 1 Chapter 1: A human cell chip for high-throughput cell imaging .................. 6 1.1 Abstract ................................................................................................. 6 1.2 Introduction ........................................................................................... 7 1.2.1 Current platforms for compact high-content screening .............. 7 1.2.2 Inspirations from yeast cell microarrays ..................................... 9 1.2.3 Advantages of the new platform of human cell microarrays ............................................................................... 10 1.3 Development of the cell printing process ............................................. 11 1.3.1 Adapting microarray printing components ............................... 11 1.3.2 Proof of concept: detecting cellular states with high density cell chip-based immunofluorescence ............................. 14 1.3.3 Troubleshooting and optimization to increase robustness against assay-related mechanical insults ................. 16 1.4 Demonstration of cell chip multiplexing and utility ............................ 17 1.5 Discussion and Remarks ....................................................................... 22 1.5.1 Constraints of the human cell chip ........................................... 23 1.5.2 Applicability of the technology across fields of study .............. 24 1.6 Materials and Methods ......................................................................... 25 1.6.1 Cell culture ............................................................................... 25 vii 1.6.2 Printing cell arrays ................................................................... 25 1.6.3 Assaying printed slides ............................................................. 26 1.6.3.1 Immunofluorescence and imaging ........................... 26 1.6.3.2 Image signal quantitation ....................................... 27 Chapter 2: Reorganization of metabolic enzymes into megastructures and compartments ...................................................... 29 2.1 Abstract ............................................................................................... 29 2.2 Introduction ......................................................................................... 30 2.3 Types of intracellular bodies ................................................................ 31 2.4 Bacterial microcompartments .............................................................. 33 2.5 Aggregates with microbodies ................................................................ 35 2.6 Fibers and foci ...................................................................................... 38 2.6.1 Fibers of metabolic proteins: carbon utilization ....................... 39 2.6.1.1 Acetyl-CoA carboxylase .......................................... 39 2.6.1.2 β-glucosidase ........................................................... 40 2.6.2 Fibers of metabolic proteins: nitrogen utilization ..................... 40 2.6.2.1 Glutamine synthetase ............................................. 40 2.6.2.2 Glutamate dehydrogenase and glutamate synthetase ............................................................... 41 2.6.3 Fibers of metabolic proteins: nucleotide biosynthesis ............... 42 2.6.3.1 Cytidine triphosphate (CTP) synthase ................... 42 2.6.3.2 Inosine 5’-monophosphate dehydrogenase, types I and II .......................................................... 46 2.6.3.3 Purine biosynthesis and purinosomes ..................... 48 2.6.4 Large-scale screens in various systems reveal many additional intracellular foci and fibers ...................................... 51 viii 2.7 Three potential roles for intracellular bodies ....................................... 56 2.7.1 Catalytic efficiency and improved regulation ........................... 57 2.7.1.1 Substrate channeling ............................................... 57 2.7.1.2 Allostery and cooperativity ..................................... 58 2.7.2 Storage depots .......................................................................... 60 2.7.3 Aggregation of dysfunctional and/or misfolded proteins ..................................................................................... 62 2.8 Speculations and conclusions................................................................ 63 2.8.1 Are metabolic enzymes intrinsically more likely to self-assemble? ............................................................................ 64 2.8.2 Protein aggregation as an evolutionary compromise ................ 67 2.8.3 A case study in ambiguity: are CTP synthase fibers cytoskeletal elements or bacterial sickle-cell disease? ............... 69 2.8.4 High prevalence of GAT domains in assembled structures .................................................................................. 71 Chapter 3: Purine biosynthesis, purinosomes, and punctate foci formed by purine biosynthesis enzymes ............................................... 74 3.1
Recommended publications
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • The Tumor Suppressor Notch Inhibits Head and Neck Squamous Cell
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2015 THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND PROGRESSION BY MODULATING PROTO-ONCOGENES AXL AND CTNNAL1 (α-CATULIN) Shhyam Moorthy Shhyam Moorthy Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cancer Biology Commons, Cell Biology Commons, and the Medicine and Health Sciences Commons Recommended Citation Moorthy, Shhyam and Moorthy, Shhyam, "THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND PROGRESSION BY MODULATING PROTO-ONCOGENES AXL AND CTNNAL1 (α-CATULIN)" (2015). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 638. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/638 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND PROGRESSION BY MODULATING PROTO-ONCOGENES AXL AND CTNNAL1 (α-CATULIN) by Shhyam Moorthy, B.S.
    [Show full text]
  • Identification of Biomarkers of Metastatic Disease in Uveal
    Identification of biomarkers of metastatic disease in uveal melanoma using proteomic analyses Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy Martina Angi June 2015 To Mario, the wind beneath my wings 2 Acknowledgments First and foremost, I would like to acknowledge my primary supervisor, Prof. Sarah Coupland, for encouraging me to undergo a PhD and for supporting me in this long journey. I am truly grateful to Dr Helen Kalirai for being the person I could always turn to, for a word of advice on cell culture as much as on parenting skills. I would also like to acknowledge Prof. Bertil Damato for being an inspiration and a mentor; and Dr Sarah Lake and Dr Joseph Slupsky for their precious advice. I would like to thank Dawn, Haleh, Fidan and Fatima for becoming my family away from home, and the other members of the LOORG for the fruitful discussions and lovely cakes. I would like to acknowledge Prof. Heinrich Heimann and the clinical team at LOOC, especially Sisters Hebbar, Johnston, Hachuela and Kaye, for their admirable dedication to UM patients and for their invaluable support to clinical research. I would also like to thank the members of staff in St Paul’s theatre and Simon Biddolph and Anna Ikin in Pathology for their precious help in sample collection. I am grateful to Dr Rosalind Jenkins who guided my first steps in the mysterious word of proteomics, and to Dr Deb Simpsons and Prof. Rob Beynon for showing me its beauty.
    [Show full text]
  • Supplementary Data.Xlsx
    Electronic Supplementary Material (ESI) for Molecular BioSystems. This journal is © The Royal Society of Chemistry 2016 Average Average spectral spectral Fold UniProt IDGene Protein Name counts- counts- enrichm negative positive ent sample sample P12821 ACE HUMAN - ACE Angiotensin-converting enzyme 0 79.75 #DIV/0! Q71U36 TBA1A HUMAN - TUBA1A Tubulin alpha-1A chain 0 59.5 #DIV/0! P17812 PYRG1 HUMAN - CTPS1 CTP synthase 1 0 43.5 #DIV/0! P23921 RIR1 HUMAN - RRM1 Ribonucleoside-diphosphate reductase large subunit 0 35 #DIV/0! P49915GUAA HUMAN - GMPS GMP synthase 0 30.5 #DIV/0! P30153 2AAA HUMAN - PPP2R1A Serine/threonine-protein phosphatase 2A 65 kDa0 regulatory subunit29 A#DIV/0! alpha isoform P55786 PSA HUMAN - NPEPPS Puromycin-sensitive aminopeptidase 0 28.75 #DIV/0! O43143 DHX15 HUMAN - DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA0 helicase28.25 DHX15#DIV/0! P15170 ERF3A HUMAN - GSPT1 Eukaryotic peptide chain release factor GTP-binding0 subunit ERF3A24.75 #DIV/0! P09874PARP1HUMAN - PARP1 Poly 0 23.5 #DIV/0! Q9BXJ9 NAA15 HUMAN - NAA15 N-alpha-acetyltransferase 15, NatA auxiliary subunit0 23 #DIV/0! B0V043 B0V043 HUMAN - VARS Valyl-tRNA synthetase 0 20 #DIV/0! Q86VP6 CAND1 HUMAN - CAND1 Cullin-associated NEDD8-dissociated protein 1 0 19.5 #DIV/0! P04080CYTB HUMAN - CSTB Cystatin-B 0 19 #DIV/0! Q93009 UBP7 HUMAN - USP7 Ubiquitin carboxyl-terminal hydrolase 7 0 18 #DIV/0! Q9Y2L1 RRP44 HUMAN - DIS3 Exosome complex exonuclease RRP44 0 18 #DIV/0! Q13748 TBA3C HUMAN - TUBA3D Tubulin alpha-3C/D chain 0 18 #DIV/0! P29144 TPP2 HUMAN
    [Show full text]
  • Author Manuscript Faculty of Biology and Medicine Publication
    Serveur Académique Lausannois SERVAL serval.unil.ch Author Manuscript Faculty of Biology and Medicine Publication This paper has been peer-reviewed but dos not include the final publisher proof-corrections or journal pagination. Published in final edited form as: Title: B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Authors: Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G Journal: Blood Year: 2017 Jan 19 Volume: 129 Issue: 3 Pages: 333-346 DOI: 10.1182/blood-2016-05-718775 In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 1 B-cell receptor driven MALT1 activity regulates MYC signaling in mantle cell lymphoma Beiying Dai,1-3 Michael Grau,1,2 Mélanie Juilland,4 Pavel Klener,5,6 Elisabeth Höring,7 Jan Molinsky,5,6 Gisela Schimmack,8 Sietse M. Aukema,9 Eva Hoster,10,11 Niklas Vogt,1,12 Annette M. Staiger,13 Tabea Erdmann,1,2 Wendan Xu,1,2 Kristian Erdmann,1,2 Nicole Dzyuba,1,2 Hannelore Madle,1,2 Wolfgang E. Berdel,2,14 Marek Trneny,6 Martin Dreyling,10 Korinna Jöhrens,15 Peter Lenz,16 Andreas Rosenwald,17 Reiner Siebert,9,18 Alexandar
    [Show full text]
  • Onderstaande Coverage Is Berekend Over 860 Exomen, Welke Geprept Zijn Met De Agilent Sureselect XT Exome V7 Kit
    Onderstaande coverage is berekend over 860 exomen, welke geprept zijn met de Agilent SureSelect XT exome v7 kit. Het sequencen is uitgevoerd op een Illumina NextSeq500 of NovaSeq6000 met een gemiddelde coverage van 100X , dekking 20x >93%. Gemiddelde Gen Coverage 20x A1BG 128 99.8 A1CF 132 99.32 A2ML1 155 99.97 A2M 148 99.72 A3GALT2 119 100 A4GALT 157 100 A4GNT 178 100 AAAS 123 100 AACS 143 97.96 AADACL2 186 99.9 AADACL3 161 100 AADACL4 170 100 AADAC 160 99.98 AADAT 138 97.39 AAED1 110 84.89 AAGAB 164 99.29 AAK1 122 99.39 AAMDC 135 90 AAMP 95 98.4 AANAT 86 99.85 AAR2 120 98.41 AARD 75 99.06 AARS2 123 99.89 AARSD1 115 94.24 AARS 134 100 AASDHPPT 157 99.75 AASDH 135 99.29 AASS 143 99.67 AATF 156 99.95 AATK 79 92.71 ABAT 136 99.16 ABCA1 149 100 ABCA2 123 96.52 ABCA3 132 99.27 ABCA4 137 96.03 ABCA5 101 94.3 ABCA6 131 98.41 ABCA7 102 99.12 ABCA8 146 99.26 ABCA9 140 99.34 ABCA10 126 94.11 ABCA12 159 99.8 ABCA13 159 97.2 ABCB1 160 99.58 ABCB4 142 99.43 ABCB5 151 99.76 ABCB6 149 99.98 ABCB7 128 99.81 ABCB8 100 93.36 ABCB9 124 97.14 ABCB10 136 90.97 ABCB11 158 99.22 ABCC1 141 96.65 ABCC2 150 99.71 ABCC3 108 96.16 ABCC4 134 95.97 ABCC5 130 96.14 ABCC6 96 92.85 ABCC8 136 99.83 ABCC9 141 99.75 ABCC10 90 99.35 ABCC11 117 99.93 ABCC12 153 99.93 ABCD1 74 83.58 ABCD2 143 99.92 ABCD3 122 92.63 ABCD4 122 99.84 ABCE1 141 98.18 ABCF1 90 99.42 ABCF2 128 99.93 ABCF3 159 100 ABCG1 135 99.71 ABCG2 143 99.77 ABCG4 122 99.91 De Coverage komt vanuit LAB-F0680_Exoom Coverage_v3.
    [Show full text]
  • Hormone and Inhibitor Treatment T47DM Cells Were Used for All Experiments Unless Otherwise Stated
    Extended Data Extended Materials Methods Cell culture; hormone and inhibitor treatment T47DM cells were used for all experiments unless otherwise stated. For hormone induction experiments, cells were grown in RPMI medium without Phenol Red, supplemented with 10% dextran-coated charcoal-treated FBS (DCC/FBS) after 24 h in serum-free conditions; cells were incubated with R5020 (10 nM) or vehicle (ethanol) as described (Vicent et al. 2011). For hormone induction experiments in MCF7 cells a similar procedure was performed; cells were grown in DMEM medium without Phenol Red, supplemented with 10% dextran-coated charcoal-treated FBS (DCC/FBS) after 24 h in serum-free conditions; cells were incubated with Estradiol (10 nM) or vehicle (ethanol). PARG and PARP inhibition were carried out via incubating cells with 5uM TA (tannic acid) or 10uM 3AB (3-amino-benzamide) respectively 1 hour prior to hormone treatment. All transfections were performed using Lipofectamine2000 (Invitrogen) according to manufacturers instructions. PAR-capture ELISA Hormone and or inhibitor treatments were carried out as described, and sample preparation was carried out as follows: At the required time point, cells were washed twice with ice-cold PBS and scraped in lysis buffer (0.4 M NaCl, 1% Triton X-100) plus protease inhibitors. Cell suspensions were then incubated for 30 min on ice with periodic vortexing. The disrupted cell suspension was centrifuged at 10,000g for 10 min at 4°C, and the supernatant was recovered, snap-frozen, and stored at 80°C until required. Ninety-six-well black-walled plates were incubated with 2 ng/mL anti-PAR monoclonal antibody (Trevigen) in 50 mM sodium carbonate (pH 7.6) overnight at 4°C.
    [Show full text]
  • Srp55 Regulates a Splicing Network That Controls Human Pancreatic Beta Cell Function and Survival
    Page 1 of 66 Diabetes SRp55 regulates a splicing network that controls human pancreatic beta cell function and survival Jonàs Juan-Mateu1,†,*, Maria Inês Alvelos1,†, Jean-Valéry Turatsinze1, Olatz Villate1, Esther Lizarraga-Mollinedo1, Fabio Arturo Grieco1, Laura Marroquí1, Marco Bugliani2, Piero Marchetti2 and Décio L. Eizirik1,3,* 1ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, 1070, Belgium. 2Department of Clinical and Experimental Medicine, Islet Cell Laboratory, University of Pisa, 56126 Pisa, Italy. 3Welbio, Université Libre de Bruxelles, 808 Route de Lennik, 1070 Brussels, Belgium. †Joint First Authors *To whom correspondence should be addressed. Tel: +3225556242; Fax: +3225556239; Email: [email protected]. Correspondence may be also addressed to [email protected]. Present address: Laura Marroquí, Cellular physiology and Nutrition Research Group, Bioengineering Institute, Miguel Hernández University, Elche, 03202, Spain. KEY WORDS: alternative splicing, pancreatic beta cell, diabetes, apoptosis, insulin secretion Diabetes Publish Ahead of Print, published online December 15, 2017 1 Diabetes Page 2 of 66 ABSTRACT Progressive failure of insulin-producing beta cells is the central event leading to diabetes, but the signalling networks controlling beta cell fate remain poorly understood. Here we show that SRp55, a splicing factor regulated by the diabetes susceptibility gene GLIS3, has a major role in maintaining function and survival of human beta cells. RNA-seq analysis revealed that SRp55 regulates the splicing of genes involved in cell survival and death, insulin secretion and JNK signalling. Specifically, SRp55-mediated splicing changes modulate the function of the pro- apoptotic proteins BIM and BAX, JNK signalling and endoplasmic reticulum stress, explaining why SRp55 depletion triggers beta cell apoptosis.
    [Show full text]
  • Original Article Prospective Target Gene Network of Key Mirnas Influenced by Long Non-Coding RNA HOXA11-AS in NSCLC Cells
    Int J Clin Exp Pathol 2017;10(3):2478-2495 www.ijcep.com /ISSN:1936-2625/IJCEP0037909 Original Article Prospective target gene network of key miRNAs influenced by long non-coding RNA HOXA11-AS in NSCLC cells Yu Zhang1*, Ting-Qing Gan2*, Xiao Wang3, Han-Lin Wang1, Xiu-Ling Zhang1, Yi-Wu Dang1, Su-Ning Huang4, Dian-Zhong Luo1, Ping Li1, Rong-Quan He2, Zu-Yun Li1, Gang Chen1 Departments of 1Pathology, 2Medical Oncology, 4Radiotherapy, First Affiliated Hospital of Guangxi Medical Uni- versity, Nanning, Guangxi Zhuang Autonomous Region, China; 3Department of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, China. *Equal contributors and co-first authors. Received August 15, 2016; Accepted August 24, 2016; Epub March 1, 2017; Published March 15, 2017 Abstract: Background: Non-coding RNAs (ncRNAs), like long ncRNAs (lncRNAs) and microRNAs (miRNAs), are con- firmed to play important roles in the tumorigenesis and deterioration of non-small cell lung cancer (NSCLC). Howev- er, the underlying expression profiling and prospective signal pathways of miRNAs associated with lncRNA HOXA11 antisense RNA (HOXA11-AS) in NSCLC remain unknown. Methods: HOXA11-AS was knocked down in A549 cell line and a microarray assay was used to detect the changes of the miRNA profiles. Four miRNA target prediction algorithms were applied to predict the potential target genes of the differentially expressed miRNAs. Bioinformatics analysis including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), protein-protein interac- tions (PPIs) and network analysis, were performed to investigate the potential functions, pathways and networks of the target genes. The different expression of HOXA11-AS between normal lung and NSCLC tissues was further verified by the data in The Cancer Genome Atlas (TCGA).
    [Show full text]
  • Differential Expression Gene Symbol Upregulated
    Table S1. 1658 differential expressed genes with P-value < 0.05 in myeloid dendritic cells patients with all ergies compared to healthy controls. Differential Gene Symbol Expression Upregulated KIAA1217, RP11-111M22.2, RP11-21M24.2, FAM221B, TRIM9, CNKSR3, LRIT3, (N=771) RP11-26J3.1, RP11-708J19.1, RPS3AP35, AC096574.4, RBPMS, JPH3, RASGRF1, RP11-118E18.4, TPPP, KCNJ9, ARMC12, TUBB8P7, KCND3, CTD-2083E4.4, SLCO5A1, EGLN3, NOS3, RPS3AP40, OR10A4, AC007551.2, RP11-110I1.12, ZNF732, RP4-800G7.3, RNFT2, SFXN2, SEPT5, UFSP1, KRT8P26, RP11- 634H22.1, RP11-357G3.1, CTC-487M23.5, RP11-804H8.6, ROPN1L, E2F2, RP11- 983P16.4, SOX12, KRTAP16-1, FAM188B, TTC28, CTB-66B24.1, PLS1, SHF, ESR1, SOCS2, MNS1, GPR55, RP11-1020A11.2, C4orf32, BHLHE22, RP11- 63E5.6, SIGLEC15, FGFBP3, AP000692.10, CTD-2357A8.3, RP1-102E24.6, ZC4H2, AC074367.1, WDR86-AS1, YPEL1, HOXB-AS1, RP3-522P13.2, OR7E47P, AC068039.4, NUDT8, IBA57, PPP1R3G, CACNB3, KB-1460A1.1, IQCJ-SCHIP1-AS1, CRHR2, CD27-AS1, RP11-368J22.2, MANSC4, FITM2, AC002467.7, RPS5P2, SNHG17, GCAT, C10orf91, CTB-61M7.1, ATP8A2P2, RP11-50E11.2, TFAP4, CTD-2060C23.1, MED9, RP11-583F2.1, GAPDHP62, RN7SL801P, CYB5RL, ALG14, IGLV5-52, AC106801.1, RP11-403A21.3, LAD1, EARS2, NEURL3, DUSP14, RP11-116K4.1, PKNOX1, RP11-248J23.5, ZNF730, PSMF1, PINLYP, HOXA10, PTMAP8, RNLS, NANOGP7, FOXD1, AIFM2, KCNJ14, AC114730.8, RP11-804H8.5, C1orf109, PANK1, RPL32P26, RP11- 528A10.2, KL, METTL21B, CTD-2186M15.1, UBE3D, SMARCA5-AS1, SCARF2, AC000003.2, AC013470.6, PEX10, LRP11, ACTBP14, RP11-93B14.5, MIR1182, LIMCH1, IFI27L1, FSTL3,
    [Show full text]
  • Genomic Profiling of Primary Histiocytic Sarcoma Reveals Two Molecular
    Hystiocyte DIsordes SUPPLEMENTARY APPENDIX Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups Caoimhe Egan, 1 Alina Nicolae, 1 Justin Lack, 2 Hye-Jung Chung, 1 Shannon Skarshaug, 1 Thu Anh Pham, 1 Winnifred Navarro, 1 Zied Abdullaev, 1 Nadine S. Aguilera, 3 Liqiang Xi, 1 Svetlana Pack, 1 Stefania Pittaluga, 1 Elaine S. Jaffe 1 and Mark Raffeld 1 1Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD; 2NIAID Collaborative Bioinformatics Resource (NCBR), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD and 3University of Virginia Health System, Charlottesville, VA, USA ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.230375 Received: June 25, 2019. Accepted: August 21, 2019. Pre-published: August 22, 2019. Correspondence: MARK RAFFELD - [email protected] Supplementary Material: Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups Caoimhe Egan1, Alina Nicolae1, Justin Lack2, Hye-Jung Chung1, Shannon Skarshaug1, Thu Anh Pham1, Winnifred Navarro1, Zied Abdullaev1, Nadine S Aguilera3, Liqiang Xi1, Svetlana Pack1, Stefania Pittaluga1, Elaine S Jaffe1 and Mark Raffeld1. 1Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 2NIAID Collaborative Bioinformatics Resource (NCBR), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 3 University of Virginia Health System, 1215 Lee Street, Box 800214, Charlottesville, VA, USA. 1 Supplementary Methods Case selection. Twenty-one cases of primary histiocytic sarcoma (pHS) with a tumor content of at least 40% were identified from the files of the Hematopathology Section of the National Cancer Institute under an IRB approved protocol.
    [Show full text]
  • Biological and Functional Characterization of the Fusion Gene NUP98-HOXA9 in Acute Myeloid Leukemia: New Therapeutic Approaches
    Tesis Doctoral Biological and functional characterization of the fusion gene NUP98-HOXA9 in Acute myeloid leukemia: New therapeutic approaches ANA DEL RIO MACHIN Madrid 2014 1 2 Departamento de Bioquímica Facultad de Medicina Universidad Autónoma de Madrid - UAM Biological and functional characterization of the fusion gene NUP98-HOXA9 in Acute myeloid leukemia: New therapeutic approaches Tesis Doctoral presentada por Ana del Río Machín Licenciada en Biología y Licenciada en Bioquímica por la Universidad de Salamanca (USAL), Máster en Biomedicina Molecular por la Universidad Autónoma de Madrid (UAM) Director: Juan Cruz Cigudosa García Grupo de Citogenética Molecular Programa de Genética del Cáncer Humano Centro Nacional de Investigaciones Oncológicas (CNIO) 3 4 Dr. Juan Cruz Cigudosa García, Jefe del Grupo de Citogenética Molecular del Programa de Genética del Cáncer Humano del Centro Nacional de Investigaciones Oncológicas (CNIO), como director de la Tesis, CERTIFICA: Que Doña Ana del Río Machín ha realizado el presente trabajo: “Biological and functional characterization of the fusion gene NUP98-HOXA9 in Acute myeloid leukemia: New therapeutic approaches” y que a su juicio reúne plenamente todos los requisitos necesarios para optar al grado de Doctor, a cuyos efectos será presentado en la Universidad Autónoma de Madrid. El trabajo ha sido realizado bajo su dirección, autorizando su presentación ante el Tribunal Calificador. Y para que conste, se extiende el presente certificado. Madrid, Octubre 2014 VºBº del Director Juan Cruz Cigudosa García 5 6 This doctoral thesis has been supported by the Spanish Government through a Formación del Profesorado Universitario (FPU) fellowship: AP2008-0339. The work was supervised by Dr. Juan Cruz Cigudosa and supported by the PI12-0425 project.
    [Show full text]